IL-8 could indicate resistance to GSK's pazopanib; HTG developing biomarker for Sanofi diagnostic;

> Interleukin-8 may be an indicator of tumor resistance and poor survival in urothelial cancer patients treated with GlaxoSmithKline's ($GSK) Phase II drug pazopanib. Press release

> Using its qNPA technology, HTG Molecular Diagnostics is collaborating with Sanofi ($SNY) to identify biomarkers for a companion diagnostic to determine those patients who will most likely to respond to an investigational agent from the drugmaker. HTG release

> Another Alzheimer's disease blood test is in development at Newcastle University that could have potential in early-stage disease. Item

> In patients with BRAF-mutated metastatic melanoma, a second mutation in MEK1 doesn't add to resistance to BRAF inhibitor drugs. Press release

> Protein Aurora-A has been linked with a number of cancers, and data presented at AACR have hooked it up with head and neck cancer, too. Release

> Bone biomarker study finds tenofovir could affect the skeleton in HIV/AIDS patients. Article

> A Metamark Genetics' prostate cancer test has completed proof of principle studies, which replicate the results of a previous positive study. Metamark release

> Israel's Micromedic Technologies has bought a third of biomarker-based cancer diagnostics company BioMarCare Technologies, with an option to gain an extra 20%. Report

> Spinal Muscular Atrophy Foundation has launched a biomarker assay panel to evaluate the severity of the disease and its progression. SMA Foundation release

> GE Healthcare ($GE) has licensed peptides binding to c-Met as diagnostics and as patient selection biomarkers in oncology; the peptides may also have uses in imaging. GE release

> Medical student gets grant to seek biomarkers for broken heart syndrome. News

> An early PET response could predict survival in patients with soft tissue sarcomas. Press release

> Legumain could be a biomarker for diagnosis and prognosis of human ovarian cancer. Abstract

> The National Cancer Institute is looking for partners to co-develop biomarkers for liver cancer. Opportunity

And Finally… Tiny starfruit-shaped gold particles could help find biomarkers. Article

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.